Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
166.41
+1.75 (+1.06%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbbVie
< Previous
1
2
3
4
5
6
7
Next >
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Via
MarketBeat
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
MarketBeat Week in Review – 2/13 - 2/17
February 18, 2023
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
February 17, 2023
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.
Via
MarketBeat
AbbVie Has a Mixed Outlook After Mixed Earnings
February 13, 2023
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold
Via
MarketBeat
Topics
Earnings
Intellectual Property
Exposures
Financial
Intellectual Property
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Via
MarketBeat
AbbVie Stock: Dividend King ABBV Overview
January 19, 2023
Via
MarketBeat
4 High-Yield Dividend Kings For 2023
January 16, 2023
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors.
Via
MarketBeat
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 06, 2023
From
Immunome, Inc.
Via
Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
MarketBeat: Week in Review 11/14 – 11/18
November 19, 2022
This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news.
Via
MarketBeat
Topics
Economy
Workforce
Exposures
Economy
Interest Rates
Layoff
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
December 01, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
MarketBeat: Week in Review 10/31-11/4
November 05, 2022
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Why is AbbVie Stock Falling, but Still Good Long-Term?
October 31, 2022
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops
October 28, 2022
AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm...
Via
PressReach
Topics
Economy
Exposures
Economy
Interest Rates
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
October 19, 2022
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain
Via
MarketBeat
Topics
Economy
Exposures
Economy
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
September 02, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
September 02, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
August 26, 2022
Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs.
Via
MarketBeat
ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV
August 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
NYSE:ABBV Long Term Shareholder Notice: Investigation of Potential Wrongdoing at AbbVie Inc.
August 10, 2022
San Diego, CA -- (SBWIRE) -- 08/10/2022 -- Certain directors of AbbVie Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Are Medtronic And Intuitive Surgical Poised For Big Growth?
August 09, 2022
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
MarketBeat: Week in Review 7/25 – 7/29
July 30, 2022
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Should You Buy AbbVie Ahead Of Earnings?
July 28, 2022
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.